Abstract
Here we report that new dual-targeted theranostic anti-cancer agents can be produced by simple conjugation of photosensitizers with tryptophan-containing peptide ligands via cyclic disulfide linkages. In the proof-of-concept study, photosensitizers conjugated with EGFR-targeting peptide GE11 (C-EGFR) were in close proximity with tryptophan residues in the conjugate, resulting in quenching of its fluorescence and singlet oxygen generation. C-EGFR specifically binds to target receptors on the cancer cell surface, after which it is internalized via receptor-mediated endocytosis. Intracellular cleavage of cyclic disulfide bonds allows separation of the photosensitizers from the tryptophan residue, after which they emit near-infrared (NIR) fluorescence and produce a phototoxic effect in the target cells.
| Original language | English |
|---|---|
| Pages (from-to) | 584-590 |
| Number of pages | 7 |
| Journal | International Journal of Pharmaceutics |
| Volume | 513 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - 20 Nov 2016 |
Bibliographical note
Publisher Copyright:© 2016 Elsevier B.V.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Activatable
- EGFR target
- Fluorescence imaging
- Photodynamic therapy
- Theranostics
Fingerprint
Dive into the research topics of 'Photosensitizer-conjugated tryptophan-containing peptide ligands as new dual-targeted theranostics for cancers'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver